Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
暂无分享,去创建一个
Mark F. Bear | Eva Loth | Jacqueline N. Crawley | Sébastien Jacquemont | Baltazar Gomez-Mancilla | Fabrizio Gasparini | M. Bear | J. Crawley | E. Loth | W. Spooren | F. Gasparini | D. Hessl | S. Jacquemont | R. Hagerman | E. Berry-Kravis | B. Gomez-Mancilla | A. Curie | V. Portes | Paul P. Wang | R. Carpenter | George G Apostol | F. Raison | A. Jønch | David Hessl | Will Spooren | L. Lindemann | F. Hossain | S. Scharf | Lothar Lindemann | Aurore Curie | Sebastian H. Scharf | Randi Hagerman | Elizabeth M. Berry-Kravis | Aia E. Jønch | George Apostol | Randall L. Carpenter | Vincent Des Portes | Farah Hossain | Florian Von Raison
[1] M. Bear,et al. Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen , 2012, Science Translational Medicine.
[2] M. Bear,et al. Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.
[3] S. Kushner,et al. Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test , 2015, Neurobiology of Disease.
[4] D. Licatalosi,et al. FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism , 2011, Cell.
[5] S. Warren,et al. The fragile X mental retardation protein inhibits translation via interacting with mRNA. , 2001, Nucleic acids research.
[6] J. Olson,et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model , 2012, Proceedings of the National Academy of Sciences.
[7] Janice Branson,et al. Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.
[8] A. Reiss,et al. Cholinergic dysfunction in fragile X syndrome and potential intervention: A preliminary 1H MRS study , 2009, American journal of medical genetics. Part A.
[9] Mark F. Bear,et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] I. Weiler,et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[11] Lisa L. Giles,et al. Challenges and Promises of Pediatric Psychopharmacology. , 2016, Academic pediatrics.
[12] H. Moll,et al. Treatment of Cognitive Deficits in Genetic Disorders: A Systematic Review of Clinical Trials of Diet and Drug Treatments. , 2015, JAMA Neurology.
[13] D. Nguyen,et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome , 2017, Journal of Neurodevelopmental Disorders.
[14] J. Crawley,et al. Normal Performance of Fmr1 Mice on a Touchscreen Delayed Nonmatching to Position Working Memory Task123 , 2016, eNeuro.
[15] Mark F. Bear,et al. Correction of Fragile X Syndrome in Mice , 2007, Neuron.
[16] P. Carlen,et al. Reduced Cortical Synaptic Plasticity and GluR1 Expression Associated with Fragile X Mental Retardation Protein Deficiency , 2002, Molecular and Cellular Neuroscience.
[17] G. Lynch,et al. Physiological Activation of Synaptic Rac > PAK Signaling Is Defective in a Mouse Model of Fragile-X Syndrome , 2010 .
[18] P. Hickmott,et al. Genetic Removal of Matrix Metalloproteinase 9 Rescues the Symptoms of Fragile X Syndrome in a Mouse Model , 2014, The Journal of Neuroscience.
[19] J. Naegele,et al. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model , 2012, Genes, brain, and behavior.
[20] R. Willemsen,et al. Fragile X syndrome: From genetics to targeted treatment , 2017 .
[21] L. Abbeduto,et al. Development of an Expressive Language Sampling Procedure in Fragile X Syndrome: A Pilot Study , 2013, Journal of developmental and behavioral pediatrics : JDBP.
[22] M. Bear,et al. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.
[23] L. Saksida,et al. The touchscreen cognitive testing method for rodents: how to get the best out of your rat. , 2008, Learning & memory.
[24] S. Rivera,et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome , 2016, Journal of developmental and behavioral pediatrics : JDBP.
[25] W. Spooren,et al. CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor , 2011, Journal of Pharmacology and Experimental Therapeutics.
[26] Ilse Gantois,et al. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice , 2013, Behavioural Brain Research.
[27] M. Bear,et al. Fragile X Syndrome From Genetics to Targeted Treatment , 2017 .
[28] Randi J. Hagerman,et al. Advances in the Treatment of Fragile X Syndrome , 2009, Pediatrics.
[29] J. Leckman,et al. Strengths and weaknesses in the intellectual functioning of males with fragile X syndrome. , 1987, American journal of mental deficiency.
[30] M. Tranfaglia,et al. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.
[31] R. Gershon,et al. The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions , 2016, Journal of Neurodevelopmental Disorders.
[32] M. Kabra,et al. Effectiveness and Safety of Donepezil in Boys With Fragile X Syndrome , 2013, Journal of child neurology.
[33] C. Erickson,et al. Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety , 2017, Journal of Neurodevelopmental Disorders.
[34] D. Nguyen,et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome , 2009, Journal of Medical Genetics.
[35] Seth M. Kelly,et al. Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome. , 2015, Cell reports.
[36] R. Maldonado,et al. Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model , 2016, Genes.
[37] Mika Nakamoto,et al. Excess Phosphoinositide 3-Kinase Subunit Synthesis and Activity as a Novel Therapeutic Target in Fragile X Syndrome , 2010, The Journal of Neuroscience.
[38] D. Nelson,et al. The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome , 2015, Cell cycle.
[39] R. Hagerman,et al. Fragile X: Leading the way for targeted treatments in autism , 2010, Neurotherapeutics.
[40] C. Gillberg. Attention deficit hyperactivity disorders , 1997, Acta paediatrica.
[41] Karl Mann,et al. Acamprosate: recent findings and future research directions. , 2008, Alcoholism, clinical and experimental research.
[42] L. Saksida,et al. New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats , 2012, Neuropharmacology.
[43] Stephen R. Morairty,et al. Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[44] B. Hamel,et al. Longitudinal changes in cognitive-behavioral levels in three children with FRAXE. , 1999, American journal of medical genetics.
[45] L. Sandler. Risperidone in children with autism and serious behavioral problems. , 2002, New England Journal of Medicine.
[46] A. Fenton,et al. Impaired cognitive discrimination and discoordination of coupled theta–gamma oscillations in Fmr1 knockout mice , 2016, Neurobiology of Disease.
[47] C. McDougle,et al. Cognitive effects of risperidone in children with autism and irritable behavior. , 2008, Journal of child and adolescent psychopharmacology.
[48] G. Lynch,et al. Physiological Activation of Synaptic Rac>PAK (p-21 Activated Kinase) Signaling Is Defective in a Mouse Model of Fragile X Syndrome , 2010, The Journal of Neuroscience.
[49] Boris Yamrom,et al. The contribution of de novo coding mutations to autism spectrum disorder , 2014, Nature.
[50] I. Weiler,et al. Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome , 2008, Journal of developmental and behavioral pediatrics : JDBP.
[51] B. D. de Vries,et al. Mental status of females with an FMR1 gene full mutation. , 1996, American journal of human genetics.
[52] R. Kravitz,et al. N-of-1 Trials in the Medical Literature: A Systematic Review , 2011, Medical care.
[53] R. Hagerman,et al. Review of targeted treatments in fragile X syndrome. , 2016, Intractable & rare diseases research.
[54] Sébastien Jacquemont,et al. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials , 2016, Science Translational Medicine.
[55] Sue Eckstein,et al. Clinical investigation of medicinal products in the paediatric population , 2003 .
[56] D. Muller,et al. Reversal of activity‐mediated spine dynamics and learning impairment in a mouse model of Fragile X syndrome , 2014, The European journal of neuroscience.
[57] E. Klann,et al. Biochemical mechanisms for translational regulation in synaptic plasticity , 2004, Nature Reviews Neuroscience.
[58] J. Montgomery,et al. AMPA Receptors as Therapeutic Targets for Neurological Disorders. , 2016, Advances in protein chemistry and structural biology.
[59] D. Ethell,et al. Open-label add-on treatment trial of minocycline in fragile X syndrome , 2010, BMC neurology.
[60] D. Hessl,et al. Improving IQ measurement in intellectual disabilities using true deviation from population norms , 2014, Journal of Neurodevelopmental Disorders.
[61] Ben A. Oostra,et al. Absence of expression of the FMR-1 gene in fragile X syndrome , 1991, Cell.
[62] S. Tonegawa,et al. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice , 2007, Proceedings of the National Academy of Sciences.
[63] C. B. Smith,et al. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome , 2015, The international journal of neuropsychopharmacology.
[64] A. Arai,et al. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. , 2007, Current drug targets.
[65] Sandra Même,et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule , 2014, Orphanet Journal of Rare Diseases.
[66] S. Kushner,et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. , 2015, The Journal of clinical investigation.
[67] A L Reiss,et al. Specification of the neurobehavioral phenotype in males with fragile X syndrome. , 1995, Pediatrics.
[68] M. Bear,et al. Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome , 2013, Neuron.
[69] S. Ceman,et al. S6K1 Phosphorylates and Regulates Fragile X Mental Retardation Protein (FMRP) with the Neuronal Protein Synthesis-dependent Mammalian Target of Rapamycin (mTOR) Signaling Cascade* , 2008, Journal of Biological Chemistry.
[70] M. Pangalos,et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.
[71] S. Tonegawa,et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 , 2013, Proceedings of the National Academy of Sciences.
[72] M. Bear,et al. Arbaclofen in fragile X syndrome: results of phase 3 trials , 2017, Journal of Neurodevelopmental Disorders.
[73] R. Paylor,et al. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome , 2011, Behavioural Brain Research.
[74] M. Caserta,et al. Exploring the Caregiver Burden Inventory (CBI): Further Evidence for a Multidimensional View of Burden , 1996, International journal of aging & human development.
[75] D. Hessl,et al. Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS) , 2012, Journal of Neurodevelopmental Disorders.
[76] M. Ghert,et al. Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.
[77] Stephen J. Guter,et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. , 2006, Journal of child and adolescent psychopharmacology.
[78] M. Bear,et al. Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial , 2012, Science Translational Medicine.
[79] Jens-Uwe Peters,et al. Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.
[80] Alcino J. Silva,et al. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.
[81] Angus C. Nairn,et al. Synaptic plasticity: one STEP at a time , 2006, Trends in Neurosciences.
[82] Ich Harmonised,et al. INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .
[83] Amy L. Donaldson,et al. Randomized, Controlled Trial of an Intervention for Toddlers With Autism: The Early Start Denver Model , 2010, Pediatrics.
[84] A. Holmes,et al. Predictably Irrational: Assaying Cognitive Inflexibility in Mouse Models of Schizophrenia , 2009, Frontiers in neuroscience.
[85] Bassem A. Hassan,et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS) , 2009, Brain Research.
[86] M. Gassmann,et al. Regulation of neuronal GABAB receptor functions by subunit composition , 2012, Nature Reviews Neuroscience.
[87] D. Chuang,et al. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. , 2010, Pharmacology & therapeutics.
[88] S. Rivera,et al. A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome , 2013, Journal of developmental and behavioral pediatrics : JDBP.
[89] C. B. Smith,et al. Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome , 2012, Neurobiology of Disease.
[90] A. Bruns,et al. Chronic Metabotropic Glutamate Receptor 5 Inhibition Corrects Local Alterations of Brain Activity and Improves Cognitive Performance in Fragile X Mice , 2014, Biological Psychiatry.
[91] Robin Christensen,et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.
[92] Aaron Isaacs,et al. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant , 2012, Psychopharmacology.
[93] Roland Heckendorn,et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.
[94] M. Bear,et al. Convergence of Hippocampal Pathophysiology in Syngap+/− and Fmr1−/y Mice , 2015, The Journal of Neuroscience.
[95] E. Klann,et al. Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice , 2016, Neuropsychopharmacology.
[96] Michael Rabbia,et al. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results , 2017, Neuropsychopharmacology.
[97] J. Crawley,et al. GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism , 2015, Neuropsychopharmacology.
[98] R. Hagerman,et al. A controlled trial of stimulant medication in children with the fragile X syndrome. , 1988, American journal of medical genetics.
[99] Nila A. Sathe,et al. Medications for Adolescents and Young Adults With Autism Spectrum Disorders: A Systematic Review , 2012, Pediatrics.
[100] W. Brown,et al. Autism spectrum disorder in children and adolescents with fragile X syndrome: within-syndrome differences and age-related changes. , 2010, American journal on intellectual and developmental disabilities.
[101] Michelle N. Ngo,et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model , 2008, Journal of Medical Genetics.
[102] J. Sweatt,et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. , 2010, Biochemical pharmacology.
[103] F. Gasparini,et al. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. , 2014, Bioorganic & medicinal chemistry.
[104] M. Bear,et al. Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. , 2010, Journal of neurophysiology.
[105] Harry T Orr,et al. Recovery from Polyglutamine-Induced Neurodegeneration in Conditional SCA1 Transgenic Mice , 2004, The Journal of Neuroscience.
[106] Ich Harmonised,et al. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .
[107] S. Warren,et al. FMR1 protein: conserved RNP family domains and selective RNA binding. , 1993, Science.
[108] J. Walker,et al. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use , 2007, Journal of clinical pharmacy and therapeutics.
[109] J. Henley,et al. Synaptic AMPA receptor composition in development, plasticity and disease , 2016, Nature Reviews Neuroscience.
[110] Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back , 2015, Neurotherapeutics.
[111] J. Turk,et al. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders , 2005, European child & adolescent psychiatry.
[112] J. Wettstein,et al. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. , 2015, Current opinion in pharmacology.
[113] L. Hartling,et al. N-of-1 trials are a tapestry of heterogeneity. , 2016, Journal of clinical epidemiology.
[114] Matthew W. Mosconi,et al. Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome , 2016, Translational Psychiatry.
[115] Masahiko Watanabe,et al. Endocannabinoid-mediated control of synaptic transmission. , 2009, Physiological reviews.
[116] A. Reiss,et al. Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. , 1999, American journal of medical genetics.
[117] J. Mandel,et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome , 1991, Science.
[118] R. B. Carter,et al. Characterization of the anticonvulsant properties of Ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acid(A) receptor , 1997 .
[119] E. Klann,et al. Genetic Removal of p70 S6 Kinase 1 Corrects Molecular, Synaptic, and Behavioral Phenotypes in Fragile X Syndrome Mice , 2012, Neuron.
[120] S. Chattarji,et al. Genetic and Acute CPEB Depletion Ameliorate Fragile X Pathophysiology , 2013, Nature Medicine.
[121] J. E. Kranz,et al. Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[122] S. McClintock,et al. 7, 8-Dihydroxyflavone induces synapse expression of AMPA GluA1 and ameliorates cognitive and spine abnormalities in a mouse model of fragile X syndrome , 2015, Neuropharmacology.
[123] L. Saksida,et al. Discrimination of multidimensional visual stimuli by mice: intra- and extradimensional shifts. , 2005, Behavioral neuroscience.
[124] C. McDougle,et al. Aripiprazole in autism spectrum disorders and fragile X syndrome , 2010, Neurotherapeutics.
[125] R. Gollub,et al. Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis , 2015, PloS one.
[126] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[127] J. Malter,et al. Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice , 2011, PloS one.
[128] D. Solís. US Food and Drug Administration , 2010 .
[129] J. Piven,et al. Longitudinal Profiles of Adaptive Behavior in Fragile X Syndrome , 2014, Pediatrics.
[130] Elizabeth A. McCullagh,et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome , 2017, Nature Network Boston.
[131] Jill L Silverman,et al. Modeling fragile X syndrome in the Fmr1 knockout mouse. , 2014, Intractable & rare diseases research.
[132] M. Dierssen,et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome , 2013, Nature Medicine.
[133] M. O. James,et al. ヘッジホッグ経路阻害剤,サリデギブ(IPI-926)はマウス髄芽腫モデルで寿命を延長する , 2012 .
[134] B. Pennington,et al. The Neurocognitive Phenotype of Female Carriers of Fragile X: Additional Evidence for Specificity , 1993, Journal of developmental and behavioral pediatrics : JDBP.
[135] Y. Paulignan,et al. A Novel Analog Reasoning Paradigm: New Insights in Intellectually Disabled Patients , 2016, PLoS ONE.
[136] G. Dawson,et al. Long-Term Outcomes of Early Intervention in 6-Year-Old Children With Autism Spectrum Disorder. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.
[137] Mark F Bear,et al. The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.
[138] C. Erickson,et al. Pharmacotherapy for Fragile X Syndrome: Progress to Date , 2016, Drugs.
[139] R. Gollub,et al. Certainty of genuine treatment increases drug responses among intellectually disabled patients , 2017, Neurology.
[140] P. Lombroso,et al. Taking STEPs forward to understand fragile X syndrome. , 2012, Results and problems in cell differentiation.
[141] Nancy D. Giles,et al. Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. , 2006, Journal of intellectual disability research : JIDR.
[142] C. McDougle,et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome , 2013, Psychopharmacology.
[143] A. Reiss,et al. A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome , 2008, Journal of Neurodevelopmental Disorders.
[144] L. Abbeduto,et al. A Spoken-Language Intervention for School-Aged Boys With Fragile X Syndrome. , 2016, American Journal on Intellectual and Developmental Disabilities.
[145] J. Epplen,et al. Point mutation frequency in the FMR1 gene as revealed by fragile X syndrome screening. , 2014, Molecular and Cellular Probes.